3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
12
Phase 2
6
Phase 1/2
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Peritoneal Neoplasms
3
Colorectal Neoplasms
3
Appendiceal Neoplasms
3
Anus Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Liver Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Urothelial Carcinoma Ureter
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Neoplasm
1
Peritoneal Diseases
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Necrosis
1
Lung Metastases
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Gastrointestinal Neoplasms
1
Dermatitis
1
Interventions
vocimagene amiretrorepvec
1
enfortumab vedotin
1
catumaxomab
1
apatorsen
1
Ty21a typhoid vaccine
1
Therapeutics
1
Photochemotherapy
1
Paclitaxel
1
Mitomycin
1
Imiquimod
1
Gemcitabine
1
Flucytosine
1
Ethacrynic Acid
1
Bevacizumab
1
BCG Vaccine
1
Antibodies
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Non-Muscle Invasive Bladder Neoplasms
×
Mitomycin
×
Clear all
NCT02316171
2022-07-27
CANON
Viralytics
Phase 1
Completed
16 enrolled
8 charts